首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.
【2h】

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

机译:第十四届加丹纪念堂演讲。他莫昔芬用于治疗和预防乳腺癌的最新观点。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tamoxifen has been found to be a safe and effective treatment for all stages of breast cancer. Long term tamoxifen therapy is associated with some rare, but potentially serious, side effects so patients should be carefully monitored. However, long term tamoxifen therapy is also associated with a number of physiological benefits over and above its tumouristatic action. These benefits include a decrease in the development of contralateral breast cancer, the maintenance of bone density in postmenopausal women and a decrease in cardiovascular disease. The successful application of tamoxifen to treat breast cancer has increased enthusiasm to test its worth to prevent breast cancer. Although there are individual requests by patients for tamoxifen to prevent breast cancer, individual treatment is inappropriate. Tamoxifen can only be adequately evaluated as a preventive in randomized, double-blind clinical trials. These trials are in place and physicians should encourage women to participate and establish a new therapeutic option as rapidly as possible.
机译:已经发现他莫昔芬对于乳腺癌的所有阶段都是安全有效的治疗方法。长期他莫昔芬疗法伴有一些罕见但潜在的严重副作用,因此应仔细监测患者。但是,长期使用他莫昔芬疗法除了具有抑瘤作用外,还具有许多生理益处。这些好处包括减少对侧乳腺癌的发生,维持绝经后妇女的骨密度以及减少心血管疾病。他莫昔芬在乳癌治疗中的成功应用增加了测试其预防乳癌价值的热情。尽管患者个别要求使用他莫昔芬预防乳腺癌,但个别治疗是不合适的。在随机,双盲临床试验中,他莫昔芬只能作为预防剂进行充分评估。这些试验已经到位,医师应鼓励妇女尽快参与并建立新的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号